Current Clinical trial News and Events

Current Clinical trial News and Events, Clinical trial News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
New breakthrough in the treatment of rheumatoid arthritis
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment, otilimab, that not only suppresses inflammation but also significantly reduces patient reported pain scores. (2020-11-25)

Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue. (2020-11-25)

Researchers create 3D-printed nasal swab for COVID-19 testing
In response to the critical shortage of nasopharyngeal (NP) swabs early in the COVID-19 pandemic, the Department of Radiology at University of South Florida (USF) Health in Tampa set out to design, validate and create NP swabs using a point-of-care 3D printer. Results of the first clinical trial of 3D-printed NP swabs for COVID-19 testing are being presented at the annual meeting of the Radiological Society of North America (RSNA). (2020-11-23)

Denmark trial measures effectiveness of adding a mask recommendation to other public health measures
Denmark trial measures effectiveness of adding a mask recommendation to other public health measures for preventing SARS-CoV-2 infection. (2020-11-18)

Immunotherapy for lung and other cancers may also be beneficial for rare skin cancer
New research from the University of North Carolina School of Medicine and the Lineberger Comprehensive Cancer Center found immunotherapies effective against lung cancer and melanoma may work against cutaneous angiosarcoma, a rare, highly aggressive skin tumor found primarily on the scalps of older White people. The researchers report tumor-infiltrating lymphocytes and the surface protein markers PD-1 and PD-L1 could help guide the choice of immunotherapy to fight cutaneous angiosarcomas. (2020-11-18)

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M. Knipe and colleagues in this Perspective. (2020-11-17)

Good long-term effects of continuous glucose monitoring
New data on continuous glucose monitoring for people with type 1 diabetes, over a significantly longer period than before, are now available. A University of Gothenburg study shows that using the CGM tool, with its continuous monitoring of blood sugar (glucose) levels, has favorable effects over several years. (2020-11-16)

New Fred Hutch-led trial shows no benefits of dairy foods for blood sugar regulation
Results from a new trial published by a team led by researchers at Fred Hutchinson Cancer Research Center suggests lower dairy intake may be beneficial for people with metabolic syndrome. (2020-11-16)

Researchers discover how to boost vaccine designed to prevent melanoma recurrence
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November. (2020-11-16)

A change of heart -- new drug for HCM reduces heart mass
For the first time, a medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, hypertrophic cardiomyopathy, rather than simply addressing their symptoms. (2020-11-16)

Cleveland Clinic led trial shows drug effective in 96% of patients with recurrent pericarditis
Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of pericarditis recurrence. The study was published today in the New England Journal of Medicine and presented at the American Heart Association's Scientific Sessions. (2020-11-16)

SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors
In these two paired trials, teams of investigators led by Brigham cardiologist Deepak L. Bhatt, MD, MPH, evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1. Results of the trials are both published in The New England Journal of Medicine and presented by Bhatt simultaneously at the Late-Breaking Clinical Trial Sessions of the American Heart Association Scientific Sessions. (2020-11-16)

Patients taking statins experience similar side effects from dummy pills
People taking dummy pills and statins experienced similar side effects in a new study. (2020-11-15)

Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF
The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers concluded that rivaroxaban worked as well as the standard anticoagulant medication warfarin. (2020-11-14)

Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
Findings from a national study published today in the Journal of the American Medical Association (JAMA) ''do not support'' the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19. (2020-11-13)

A few kilograms weight loss nearly halves the risk of diabetes
Losing a few kilograms in weight almost halves people's risk of developing Type 2 diabetes - according to a large scale research study. The research shows how providing support to help people with prediabetes make small changes to their lifestyle, diet and physical activity can almost halve the risk of developing Type 2 diabetes. The findings come from the largest diabetes prevention research study in the world in the last 30 years. The clinical trial involved >1,000 people with prediabetes. (2020-11-13)

Antidepressant may prevent severe COVID-19, trial suggests
The antidepressant fluvoxamine appears to prevent COVID-19 infections from worsening and may help keep patients out of the hospital, a trial based on research from the University of Virginia School of Medicine suggests. (2020-11-13)

Study: Vitamin D, fish oil don't lower atrial fibrillation risk
New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance. (2020-11-13)

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. (2020-11-12)

Exoskeleton-assisted walking improves mobility in individuals with spinal cord injury
''Participants showed improvement regardless of level of injury, completeness, or duration of injury,'' noted Dr. Forrest, ''indicating that exoskeletons can be used to improve mobility across a broad spectrum of individuals with neurological deficits caused by spinal cord injury. Our results can be used to guide the application of exoskeletons to spinal cord injury rehabilitation, and the timely acquisition of skills for the safe use of these devices for rehabilitation and community use.'' (2020-11-12)

JAMA reports fluvoxamine as potential early treatment for COVID-19
The COVID-19 Early Treatment Fund (CETF) announced that JAMA, The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that investigated whether the antidepressant medication fluvoxamine can reduce the risk for respiratory deterioration. (2020-11-12)

Vitamin D and Omega-3s bolster health in some active older people
The DO-HEALTH study led by Zurich-based geriatrician Professor Heike Bischoff-Ferrari has examined the effects of simple measures on the health of healthy adults aged 70 or older. Initial analyses suggest that vitamin D, omega-3 fatty acids and strength-training exercises do not significantly improve bone health, leg function and memory. Nevertheless, certain groups of people could still benefit from these measures. (2020-11-11)

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) . (2020-11-11)

Personalized cancer vaccine clinical trial to expand following promising early results
A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center. (2020-11-10)

New research supports clinical utility of CTC count for metastatic breast cancer
Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer. Published in the November issue of JAMA Oncology, this is the first study to support clinical utility of CTC count in a randomized clinical trial. (2020-11-09)

Nut consumption causes changes in sperm DNA function
Researchers have evaluated for the first time the effect of a short/middle-term consumption of a mixture of tree nuts (almonds, hazelnuts and walnuts) on sperm DNA methylation patterns in healthy individuals reporting eating a Western-style diet. They have observed that the methylation of 36 genomic regions was significantly different between baseline and the end of the trial only in the group that consumed nuts, and 97.2% of the regions displayed hypermethylation. (2020-11-09)

$1 million to support manufacturing of COVID-19 treatments, vaccines at uOttawa, Ottawa Hospital
Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 million from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19. (2020-11-09)

All weight loss isn't equal for reducing heart failure risk
DALLAS - Nov. 9, 2020 - Reducing the level of body fat and waist size are linked to a lower risk of heart failure in patients with type 2 diabetes, a study led by UT Southwestern researchers indicates. The findings, reported today in Circulation, suggest that all weight loss isn't equal when it comes to mitigating the risk of heart disease. (2020-11-09)

Vitamin D lessens symptoms of severe eczema in children
Vitamin D supplementation eased the symptoms experienced by children with severe atopic dermatitis, or eczema, in a recent randomized controlled trial published in Pharmacology Research & Perspectives. (2020-11-04)

Healthcare app reduces symptoms of COPD compared to regular treatment
A Southampton-developed healthcare app that helps people with Chronic Obstructive Pulmonary Disease (COPD) manage their condition can speed up recovery after hospital admission and reduce flare-ups of symptoms, a newly published study has shown. (2020-10-30)

Giving the immune system a double boost against cancer
Cancer immunotherapies are very effective for some patients, but many cancers do not respond to the currently available treatments. Researchers are developing a new approach that expands the number of treatable tumor types. (2020-10-30)

Intensive urate lowering reduces urine albumin excretion
Phase 2 trial of verinurad with febuxostat vs. placebo shows 49% reduction in albuminuria (2020-10-29)

Validation of ERCC1/2 signature as radiosensitivity biomarker for tumor & normal tissues in NSCLC
A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway. These findings were presented at the virtual edition of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2020. (2020-10-28)

Outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer
Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants. (2020-10-28)

Study in Nature Medicine shows superior patient outcomes in LLS's Beat AML clinical trial
Study in Nature Medicine shows superior outcomes for patients in LLS's paradigm-shifting beat AML clinical trial. (2020-10-27)

Radiosurgery reduces cognitive decline without compromising survival for pts with 4+ brain mets
Results of a new randomized phase III trial suggest that stereotactic radiosurgery (SRS) should replace whole brain radiation therapy (WBRT) as the standard of care for patients with four or more brain metastases. Results from the clinical trial (NCT01592968) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. (2020-10-26)

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer. The phase II NRG Oncology NRG-RTOG 0712 trial evaluated two regimens. One was the prior RTOG standard using 5-flourouracil and cisplatin with twice daily radiation (FCT), and the other a regimen of gemcitabine and daily radiation (GD) which had demonstrated efficacy in single institution clinical trials. (2020-10-26)

Photon IMRT treatment group displays no significant survival difference between arms
A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM). (2020-10-26)

Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, & other solid tumors
A novel agent that targets a mutated form of the KRAS gene - the most commonly altered oncogene in human cancers and one long considered ''undruggable'' - shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online. (2020-10-25)

Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors
New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations to the 32nd EORTC-NCI-AACR cancer symposium, researchers involved in the KRYSTAL-1 phase I/II clinical trial said that adagrasib (MRTX849) showed clinical activity and manageable adverse side effects in patients with non-small cell lung cancer, colorectal cancer and other solid tumours. (2020-10-25)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.